Necrotizing enterocolitis: recent advances in treatment with translational potential
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · May 2023 · 1 min read
In brief
In brief
This review examines emerging therapeutic strategies for necrotizing enterocolitis (NEC), a devastating neonatal gastrointestinal disorder with persistently high mortality. Novel approaches include remote ischemic conditioning, stem cell therapy, breast milk-derived components, fecal microbiota transplantation, and immunotherapy, with discussion of their translational potential and clinical limitations.
Written by the GCMD Library team from the article.
Abstract
Necrotizing enterocolitis (NEC) is one of the most prevalent and devastating gastrointestinal disorders in neonates. Despite advances in neonatal care, the incidence and mortality due to NEC remain high, highlighting the need to devise novel treatments for this disease. There have been a number of recent advancements in therapeutic approaches for the treatment of NEC; these involve remote ischemic conditioning (RIC), stem cell therapy, breast milk components (human milk oligosaccharides, exosomes, lactoferrin), fecal microbiota transplantation, and immunotherapy. This review summarizes the most recent advances in NEC treatment currently underway as well as their applicability and associated challenges and limitations, with the aim to provide new insight into the paradigm of care for NEC worldwide.